- AATOD Releases Using Medication Assisted Treatment to Treat Opioid Use Disorder from Past Experience to Guide Policy
- AMA Calls On States To Remove Prior Authorization For Opioid Treatment
- Some Drug Users in Western U.S. Seek Out Deadly Fentanyl. Here’s Why.
- Opioids Fueled A Doubling Of Suicides And Overdoses In The US
- Opioid Crisis Roadmap Overlooks Gender
- Medicaid: What to Watch in 2019 from the Administration, Congress, and the States
- Would Heroin Vaccine Work? Experimental Drug To Be Tested In Syracuse
- Fatal Drug ODs Soaring Among Middle-Aged Women: CDC
LINKS TO ADDITIONAL NEWS OF INTEREST
- This Is How America Is Failing Its Young Opioid Generation – 1/7/19
- Learning With ‘Heroin Addiction Explained: How Opioids Hijack the Brain’ – 1/8/19
- Does opioid use in pets create higher risk for abuse in humans? – 1/11/19
AATOD Releases Using Medication Assisted Treatment to Treat Opioid Use Disorder from Past Experience to Guide Policy
According to Mark Parrino MPA, “This policy paper is being released as our country continues to grapple with the challenges of the opioid use epidemic. It provides a historical context regarding the use of Medication Assisted Treatment for Opioid Use Disorder. It also provides a broad context to a number of current policy debates about the value of clinical support services when medications are used to treat Opioid Use Disorder in addition to how the criminal justice system appears to be taking greater interest to how MAT can be used in correctional facilities and Drug Courts.”
The paper also deals with a number of reimbursement issues including the recent Congressional action to implement a Medicare reimbursement for Medicare eligible patients in OTPs in addition to increasing Medicaid reimbursement in the states for OTP patients and the emergence of commercial carriers.”
- Executive Summary
- Brief History of Opioid Addiction Treatment in the United States
- Lessons Learned from Regulatory Oversight
- Lessons Learned: The Value of OTP Services
- Lessons Learned in Favor of Clinical Support Services
- Federal Guidance/Clinical Treatment Recommendations
- The Use of Buprenorphine to Treatment Opioid Use Disorder
- DATA 2000 Practices: The Forgotten Value of Oversight
- Lessons Learned from Treatment Expansion
- The Diversion of Federally Approved Medications: Is it a Problem?
- Buprenorphine Diversion
- The Importance of Treatment Coordination
- Where We Are Today
- The Emerging Importance of Criminal Justice
- Who Pays for Treatment
The policy paper can be accessed at: http://www.aatod.org/wp-content/uploads/2019/01/2019-Policy-Paper-4.pdf
Source: AATOD.org – January 10, 2019
Categories: Addiction, Drug Courts & Criminal Justice, Medication-Assisted Treatment (MAT), News Updates, Opioid Abuse/Addiction, Opioid Treatment Programs (OTPs), Opioids
Tags: AATOD, Addiction, Criminal Justice, Medication-Assisted Treatment
“Following the news that Pennsylvania will remove prior authorization requirements for medication-assisted treatment (MAT) for opioid-use disorder, the president of the American Medical Association (AMA) called on payers in every state to do the same.
“Payers across the nation commonly impose prior-authorization requirements that patients and physicians must meet before medications are available for treatment,” said Barbara McAneny, AMA president, in a statement. “When patients seek help, it is unconscionable to make them wait days or weeks for the right treatment.”
Source: Pharmacist.com – January 7, 2019
“Ever since the powerful synthetic opioid fentanyl started showing up in the U.S. illicit drug supply eight years ago, experts have surmised that drug traffickers were using the inexpensive white powder to boost the potency of heroin, sometimes adding too much and inadvertently killing their customers.
In a series of interviews with heroin users in Rhode Island in 2017, Brown University researchers reported that users “described fentanyl as unpleasant, potentially deadly, and to be avoided.” They concluded that demand for the deadly contaminant was low and that its presence in the drug supply was “generating user interest in effective risk mitigation strategies, including treatment.”
But here in San Francisco’s gritty Tenderloin district, where fentanyl was only rarely seen until last year, drug users tell a starkly different story. For many of them, fentanyl is a high-value drug that, if used carefully, can prevent dope sickness and deliver a strong high for a fraction of the price of heroin.”
Source: PewTrust.org – January 7, 2019
“Suicides and drug overdoses kill American adults at twice the rate today as they did just 17 years ago, and opioids are a key contributor to that rise, according to a new review and analysis by a University of Michigan team.
Reversing this deadly double trend will take investment in programs that have been proven to prevent and treat opioid addiction, the authors of the study say in a new article in the New England Journal of Medicine.
They also call for more research to identify who’s most at risk of deliberate or unintentional opioid overdoses, to make sure these individuals get better pain management, mental health care and medication-assisted therapy for opioid addiction.”
Source: Eurekalert.org – January 7, 2019
“Women’s Health Research at Yale (WHRY) is calling on a government committee to revise its report on a coordinated response to the opioid epidemic so that it reflects the unique needs of women.
In a commentary published in the peer-reviewed journal Biology of Sex Differences, WHRY Director Carolyn M. Mazure, Ph.D., and Jill Becker, Ph.D., chair of the Biopsychology Area of the University of Michigan Psychology Department, detailed the laboratory, clinical, and epidemiological evidence showing the need for the report to endorse and encourage the research of sex and gender differences. They argued such data is necessary to generate gender-based interventions that more fully address the opioid epidemic.
“All data must be reported by sex and gender so that gender-specific treatment and prevention strategies derived from this research are provided to practitioners and the public,” the authors said. “We encourage biomedical researchers and clinical care providers, as well as the public, to insist that a successful response to the opioid crisis should highlight the importance of understanding sex and gender differences in the current opioid epidemic.”
Source: Eurekalert.org – January 6, 2019
“Medicaid, the provider of health insurance coverage for about one in five Americans and the largest payer for long-term care services in the community and nursing homes, continues to be a key part of health policy debates at the federal and state level. Important Medicaid issues to watch in 2019 include Medicaid expansion developments amid ongoing litigation about the ACA’s constitutionality as well as Medicaid demonstration waiver activities, including those focused on work requirements and other eligibility restrictions.
Finally, reforms in benefits, payment and delivery systems continue to evolve as states and the federal government focus on managed care, social determinants of health, prescription drugs, and community based long-term care. While beyond the scope of this brief, Congress and states could also consider broader health reform that could expand the role of public programs in health care including Medicare for All or Medicaid buy-in programs that could have significant implications for Medicaid.”
Source: KFF.org – January 8, 2019
“Upstate Medical University is part of a research project developing a vaccine to prevent heroin users from getting addicted to and high on the illegal drug.
Researchers at Upstate and the Walter Reed Army Institute of Research in Maryland have received a $3.7 million grant to conduct clinical trials on an experimental heroin vaccine.
The vaccine was developed by researchers in Walter Reed’s Military HIV Research Program and the National Institute on Drug Abuse. In preclinical studies, the vaccine produced antibodies that stopped heroin from entering the brains of mice and rats for up to three months.”
Source: Syracuse.c0m – January 9, 2019
“The rate at which middle-aged American women die from overdoses involving opioids and other drugs nearly quadrupled between 1999 and 2017, new government data shows.
In 1999, about seven out of every 100,000 deaths among U.S. women aged 30 to 64 was caused by a drug overdose, but by 2017 that rate had risen to about 24 women per 100,000 — a 260 percent increase, the U.S. Centers for Disease Control and Prevention said.
At the same time, rates of fatal ODs from opioids, specifically, rose nearly sixfold for middle-aged women.
The steepest increase was actually seen among older women — those aged 55 to 64 — noted a team led by Karin Mack, of the CDC’s National Center for Injury Prevention and Control.”
Source: USNews.com – January 10. 2019